Liquid Gold, Sold by the Gram

A Billion-Dollar Category Built on a Calf's First Meal

Somewhere between the greens powder and the mushroom coffee, colostrum arrived. It shows up in my inbox more than almost anything else right now, usually phrased the same way: my friend swears her skin changed. The jars are cream-colored and expensive. The copy talks about "400+ bioactive nutrients" and proprietary cold-chain processing. The category is variously estimated at somewhere between $1.8 billion and $3.6 billion depending on which market-research firm you believe, and those are vendor reports rather than audited numbers, so treat the range as a rough shape rather than a fact.¹⁶

What's being sold is bovine colostrum: the thick, yellow first milk a cow produces in the hours after calving. It is genuinely remarkable stuff. It is also, and this is the entire problem in one sentence, remarkable for a newborn calf.

I want to be careful here, because the reflexive skeptic's move is to lump colostrum in with the sea moss and the celery juice and walk away. That would be wrong. Colostrum has a real clinical literature. There are two independent meta-analyses showing a consistent effect on respiratory symptoms in athletes.^1,2 There is a plausible, mechanistically coherent story about the gut. That is more than most viral supplements can produce, and it deserves to be said plainly before I start taking things apart.

But the trials that found something used twenty grams a day, in hard-training young men, and measured a sugar ratio in urine. The product on your counter delivers about four grams a day and the label implies glowing skin. Those are not the same claim. This issue is about the distance between them.

Built for an Animal With a Door That Closes

A calf is born without functional immunity. Unlike a human infant, it receives no antibodies across the placenta. It has roughly a day to acquire them by mouth or it will likely die of infection. Evolution's answer is colostrum: first milk loaded with immunoglobulin G, lactoferrin, insulin-like growth factor 1, transforming growth factor beta, and a long list of oligosaccharides and antimicrobial peptides.

And crucially, evolution's answer includes a delivery mechanism. For about the first twenty-four hours of life, the calf's intestinal lining performs receptor-mediated transcytosis, shuttling intact immunoglobulin molecules whole across the gut wall into the bloodstream. Then the window shuts. Farmers call it "gut closure," and it is the single most important fact in this entire article.

You do not have that window. Neither do I. It closed in cattle within a day of birth and it does not exist in adult humans at all. Whatever an adult gets from swallowing colostrum, it is not systemic delivery of intact bovine antibodies into the bloodstream. Any real effect has to be local — something happening in the lumen of the gut, on the surface of the epithelium, before digestion finishes the job.

That single constraint quietly invalidates most of the marketing. "Cellular health." "Whole-body immunity." Skin. Hair. Every claim that requires the molecule to reach a tissue outside the digestive tract is starting from a mechanistic deficit that the brand has to make up with evidence. As we'll see, it doesn't.

Three Percent

Before we can discuss whether colostrum does anything, we have to establish how much of it survives to try. Immunoglobulin G is a protein. Your stomach is an acid bath containing pepsin, followed by a small intestine full of trypsin and chymotrypsin. Proteins are exactly what that system is designed to dismantle.

The best synthesis of the human digestibility data comes from a 2015 review in Nutrition Journal, and the numbers are humbling.¹³ Across studies measuring intact bovine IgG recovery after passage through the adult gastrointestinal tract, results range from trace amounts up to about 25 percent. One human study in healthy adults found roughly three percent survived intact. Ileal effluent studies found about 19 percent of immunoglobulin remained immunologically active; jejunal sampling found 59 percent, but that figure comes from two subjects. Earlier work using nitrogen-15 labeled protein reached the same conclusion in different words: colostral immunoglobulins are only partially resistant to digestion.¹⁴

There is one more detail in that review worth knowing, because it demolishes a ritual. Co-administering antacids or omeprazole — raising gastric pH, which ought to spare the protein — did not improve IgG survival.¹³ The "take it on an empty stomach with water, never with food" protocol that circulates in every colostrum community has no demonstrated pharmacokinetic basis. It may make people feel like they're doing it right. It does not appear to change what arrives.

So: a variable and mostly small fraction survives, it stays in the gut lumen, and it cannot cross into circulation. That is the honest starting position. Everything that follows has to work within it.

A Urine Sugar Ratio, and What It Can't Tell You

Here is where the real evidence lives, and where I want to give colostrum full credit before qualifying it.

Intestinal permeability is measurable. You give someone two sugars — typically lactulose, a big molecule, and mannitol or rhamnose, a small one — and measure the ratio that appears in urine. More of the big sugar getting through means a leakier barrier. It is a legitimate physiological assay used in real gastroenterology.

Strenuous exercise in the heat transiently increases that ratio. Non-steroidal anti-inflammatories do too. And in small, well-designed crossover trials, colostrum blunts both effects.

The companion finding, from the same research group, is the indomethacin study: seven healthy men, crossover design, in which a non-steroidal anti-inflammatory tripled the permeability ratio and co-administered colostrum prevented it.⁶ That's a real and interesting result. It is also seven people.

Pooling helps somewhat, but not as much as the abstract implies. A 2024 meta-analysis in Digestive Diseases and Sciences gathered ten randomized trials and reported statistically significant reductions in both permeability ratios.³ Read past the headline and it gets murkier.

Then there is the trial that never appears in brand marketing. In 2009, Buckley and colleagues gave thirty healthy men eight weeks of run training on 60 g/day of colostrum, whey, or nothing — three times the standard study dose — and found colostrum increased intestinal permeability.⁷ Ten people per arm, so not decisive. But it is a larger dose, a longer duration, and the opposite direction, and its absence from every "the science is clear" brand page is itself informative.

One more framing point, and it's the one I'd most like readers to keep. Every trial above measures a surrogate. Nobody has demonstrated that nudging a urinary sugar ratio makes a person feel better, function better, or get sick less. And the thing colostrum is sold to fix — "leaky gut syndrome" — is not a diagnosis. There is no ICD code, no diagnostic criteria, no validated symptom cluster. Intestinal permeability is real physiology. "Leaky gut" is a marketing container built around it, and a product that treats a condition without a definition can never be shown to have failed.

Forty-Four Percent Fewer Sniffle Days, Self-Reported

This is colostrum's strongest card, and I'll play it fairly.

A 2016 meta-analysis in BMC Sports Science, Medicine and Rehabilitation pooled five randomized trials of exercising adults — 152 people total, 80 percent male, 8 to 12 weeks, 10 to 20 g/day.¹ Upper respiratory symptom days fell with a rate ratio of 0.56 (95% CI 0.43–0.72), a 44 percent reduction. Symptom episodes: rate ratio 0.62 (95% CI 0.40–0.99). There was even a dose-response signal, with 20 g/day trials outperforming 10 g/day. A separate 2022 meta-analysis of seven trials and 445 participants found a pooled risk ratio of 0.64 for respiratory infection incidence.² Two independent teams, same direction, decent magnitude.

Now the caveats, most of which come from the authors themselves rather than from me.

There is a conflict-of-interest thread running through this literature that I don't think is sinister but do think readers should know about. The first author's doctoral work was funded through a collaboration with a dairy company supplying colostrum to a supplement brand, and he is also first author on one of the five included trials, which used that brand's product.¹ All five trials used manufacturer-supplied colostrum. Most of this is properly disclosed. But there is no large, independent, publicly funded confirmatory trial anywhere in this field, and that absence is conspicuous for a category this size.

Then there's the mechanism, which was tested and failed. If colostrum works by delivering immunoglobulins, you'd expect immunoglobulin markers to move. A 2020 meta-analysis of ten trials and 239 participants found colostrum had "no or fairly low impact" on serum IgA, serum IgG, lymphocytes, neutrophils, or salivary IgA.⁴ The antibody story that sells the product is not the mechanism producing the symptom reduction. Nobody currently knows what is.

And the most recent large adult trial is weaker than its abstract suggests.

So: a genuine, replicated signal on self-reported symptoms in athletes, resting on small trials, mostly at high risk of bias, using unverified outcomes, funded within the industry, and operating through a mechanism that has been directly tested and found absent. "Promising" is defensible for that specific claim in that specific population. It is not what's on the jar.

Zero

I do dermatology. So this is the section I went looking for hardest, and it is the cleanest finding in this entire review.

There are no published randomized controlled trials of oral bovine colostrum with a skin or hair endpoint in adults. Not small ones. Not underpowered ones. Not industry-funded ones. Zero.

I went through the citation list on one leading brand's own research page — the section explicitly headed as studies on colostrum, skin health, and hair growth. It offers eight references. Every one is a narrative review of milk proteins in cosmetics, an in-vitro study of colostrum-derived exosomes on cultured skin cells, a study of oral lactoferrin in hairless mice, a probiotics review, or a review of IGF-1 and hair growth that does not involve colostrum at all. Not one is a human trial of the product category on a skin or hair outcome.

The closest thing to relevant evidence anywhere in the literature is a 2024 cosmetic study of a cream containing sheep colostrum, applied topically, in 52 women aged 40 to 70.¹⁵ Different species, different route of administration, different product entirely. It cannot be used to support swallowing bovine colostrum powder.

Cleveland Clinic's registered dietitian Beth Czerwony put it about as economically as it can be put when asked about the hair, skin and nails claim: "There are no studies that support this claim."¹⁷

I'll add the mechanistic version, because it matters more than the citation count. For colostrum to improve your skin, something in it would have to survive an adult stomach, cross an intestinal barrier that lost its transport machinery before the calf was a day old, enter circulation, reach the dermis, and act there. Every link in that chain is either unmeasured or contradicted. This isn't thin evidence. It's absent evidence for a claim that starts out mechanistically implausible.

Twenty Grams in the Trial, One in the Scoop

If you remember one thing from this issue, make it this one, because it applies to almost every supplement you will ever evaluate.

The trials that found effects used 10 to 60 grams per day, most commonly 20. That is a serious protein dose — a scoop-and-a-half of whey, roughly. It is what Marchbank used,⁵ what the higher-performing arm of the athlete meta-analysis used,¹ what the body-composition trial used.¹¹

A leading retail colostrum product uses a one-gram serving, with four or more servings suggested for the more enthusiastic protocols. Call it four grams a day. That is one-fifth of the standard effective study dose, and the dose-response signal in the athlete data runs the wrong way for that — the 10 g/day trials underperformed the 20 g/day trials.¹

You cannot inherit a trial's result while using a fifth of its dose. Even if every optimistic reading of the gut and immune literature is correct, the commercial product is not delivering the exposure that produced those results. At current pricing — roughly $99 to $120 for a 30-day supply at recommended use for the premium brands, with mass-market options well under $30 — you are paying a substantial premium for a dose the literature has not tested.

There is a population problem stacked on top of the dose problem. The evidence base is overwhelmingly young male athletes under heavy training or heat stress: people with a specific, transient, exercise-induced barrier disruption. If you are a sedentary adult with no baseline barrier defect, there is nothing in these trials showing there is anything to fix, let alone that colostrum fixes it. The epidemiologist Tim Spector's criticism is that these studies "often used male athletes rather than groups representative of the general population," and on this literature he is simply right.¹⁸

Four Things Worth Knowing Before You Buy

The sourcing question deserves a sentence too, because readers ask about it and there are two defensible positions. Industry says "calf first": a cow produces far more colostrum than a calf needs — averages around nine pounds against a calf's requirement of roughly four — so only surplus is collected. Critics counter that colostrum is inseparable from industrial dairy, where calf-dam separation is routine, male calves go to veal, and dams are eventually slaughtered. Spector's version is blunter than mine would be: he calls it cruel, and adds that it is "unlikely to do anything significant for your health in return."¹⁸ I'll leave the ethics to you. I only note that "sustainably sourced surplus" is doing a lot of quiet work on some of these labels.

Real Evidence, About a Different Product